Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported share transactions in company common stock. On February 12, he completed an open-market sale of 7,032 shares at a weighted average price of $76.55 under a Rule 10b5-1 trading plan adopted on June 16, 2025. That same day, 3,173 shares and, on February 14, 2,403 shares were withheld to cover tax liabilities tied to vesting of previously granted restricted stock awards, at prices of $76.70 and $77.36, respectively. Following these transactions, Mutz directly held 90,163 ANI Pharmaceuticals shares.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 21,986 shares at a weighted average price of $77.01 per share. Following the reported transactions, holdings were 358,574 shares.
ANI Pharmaceuticals SVP Ori Gutwerg reported tax-withholding share transactions tied to restricted stock vesting. On February 12, 1,775 shares of common stock were withheld at $76.7 per share, and on February 14, 1,888 shares were withheld at $77.36 per share.
These dispositions were made to cover tax obligations in connection with the vesting of 3,917 and 3,691 previously granted restricted shares. After these transactions, Gutwerg directly owned 76,094 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported tax-withholding share transactions in company stock. On February 12, 2026, 1,608 shares of common stock were disposed of at $76.70 per share as a tax-withholding disposition tied to restricted stock vesting. On February 14, 2026, a further 1,717 shares were disposed of at $77.36 per share, also to cover tax obligations on vesting restricted stock awards.
After these transactions, Gassert directly beneficially owned 66,021 shares of ANI Pharmaceuticals common stock and indirectly beneficially owned 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals’ SVP and Chief HR Officer Krista Davis reported tax-related share dispositions connected to restricted stock vesting. On February 12, 2026, 1,180 shares of common stock were disposed of at $76.70 per share for tax withholding, leaving 54,367 shares held directly. On February 14, 2026, a further 1,290 shares were disposed of at $77.36 per share for tax withholding, resulting in 53,077 common shares held directly afterward. The footnotes state these were shares withheld for taxes upon vesting of 3,264 and 3,020 restricted stock shares previously granted.
ANI Pharmaceuticals senior executive Meredith W. Cook reported several stock transactions involving company common shares. On February 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock in an open-market sale at an average price of $76.8 per share under a Rule 10b5-1 trading plan adopted on September 15, 2025.
On February 12 and February 14, 2026, a total of 3,313 shares were withheld to cover tax obligations in connection with the vesting of previously granted restricted stock awards, at prices of $76.7 and $77.36 per share, respectively. After these transactions, she directly owned 67,550 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported tax-withholding share dispositions related to restricted stock vesting. On February 12, 2026, 2,829 shares of common stock were withheld at $76.7 per share to cover taxes on 6,202 vested restricted shares. On February 14, 2026, 2,448 shares were withheld at $77.36 per share to cover taxes on 5,368 vested restricted shares. After these non-market transactions, Carey directly beneficially owned 170,083 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On February 11, 2026, 5,503 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes in connection with the vesting of 16,210 performance stock units, a grant originally reported on April 6, 2023. After this non‑open‑market, tax‑withholding transaction, Carey directly beneficially owns 175,360 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Meredith Cook reported a tax-related share disposition. On February 11, 2026, 3,011 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to equity compensation.
The filing explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, previously granted on April 6, 2023. After this tax-withholding transaction, Cook directly beneficially owned 71,363 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share as a tax-withholding disposition related to equity compensation.
The footnote explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, a grant originally reported on April 6, 2023. After this transaction, Davis directly owned 55,547 shares of ANI Pharmaceuticals common stock.